XNASAKBA
Market cap423mUSD
Jan 15, Last price
1.94USD
1D
2.65%
1Q
45.86%
Jan 2017
-81.36%
IPO
-91.81%
Name
Akebia Therapeutics Inc
Chart & Performance
P/E
—
P/S
2.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.91%
Rev. gr., 5y
-1.30%
Revenues
195m
-33.49%
Net income
-52m
L-51.02%
CFO
-23m
L-68.03%
Earnings
Mar 12, 2025
Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 194,623 -33.49% | 292,602 37.00% | |||||||
Cost of revenue | 237,461 | 352,609 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (42,838) | (60,007) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 13,447 | ||||||||
Tax Rate | |||||||||
NOPAT | (42,838) | (73,454) | |||||||
Net income | (51,925) -51.02% | (106,009) -56.71% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,793 | 7,121 | |||||||
BB yield | -2.92% | -6.75% | |||||||
| Debt | |||||||||
Debt current | 24,039 | 36,744 | |||||||
Long-term debt | 89,090 | 96,744 | |||||||
Deferred revenue | 43,296 | 43,296 | |||||||
Other long-term liabilities | 48,978 | 111,397 | |||||||
Net debt | 70,204 | 40,319 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (23,384) | (73,154) | |||||||
CAPEX | (114) | ||||||||
Cash from investing activities | (114) | ||||||||
Cash from financing activities | (25,206) | 14,598 | |||||||
FCF | (18,040) | (73,691) | |||||||
| Balance | |||||||||
Cash | 42,925 | 90,466 | |||||||
Long term investments | 2,703 | ||||||||
Excess cash | 33,194 | 78,539 | |||||||
Stockholders' equity | (1,608,942) | (1,552,905) | |||||||
Invested Capital | 1,774,814 | 1,816,723 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 187,465 | 182,783 | |||||||
Price | 1.24 114.90% | 0.58 -74.47% | |||||||
Market cap | 232,457 120.41% | 105,466 -71.88% | |||||||
EV | 302,661 | 145,785 | |||||||
EBITDA | (992) | (22,310) | |||||||
EV/EBITDA | |||||||||
Interest | 6,032 | 15,687 | |||||||
Interest/NOPBT | |||||||||